TScan Therapeutics, Inc.
TScan Therapeutics, Inc. (Nasdaq: TSCN) is a fully integrated clinical-stage biotechnology company focused on developing T cell receptor-engineered T cell therapies for treating patients with cancer and autoimmune disorders. The company's website is www.tscan.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What TScan Therapeutics, Inc. does
In the company’s own words
TScan Therapeutics, Inc. (Nasdaq: TSCN) is a fully integrated clinical-stage biotechnology company focused on developing T cell receptor-engineered T cell therapies for treating patients with cancer and autoimmune disorders. The company's website is www.tscan.com.
TScan's lead product candidate, TSC-101, targets HA-2 antigen and is in Phase 1 clinical development for treating acute myeloid leukemia and myelodysplastic syndrome patients undergoing allogeneic hematopoietic cell transplantation. The company is expanding its hematologic malignancies program with additional TCR-T candidates, TSC-102-A01 and TSC-102-A03, which target CD45 antigen across different HLA types. These candidates are designed to eliminate residual cancer cells and prevent relapse following bone marrow transplantation.
Beyond hematologic malignancies, TScan is developing multiplex TCR-T therapy candidates for solid tumors, targeting antigens including HPV16, MAGE-A4, and PRAME. The company is pursuing an in vivo engineering platform to deliver off-the-shelf TCR-T therapies. Additionally, TScan is leveraging its target discovery platform to identify treatments for T cell-driven autoimmune disorders, with initial focus on ankylosing spondylitis, ulcerative colitis, and scleroderma. The company maintains a research collaboration with Amgen to identify antigens in Crohn's disease patients, under which TScan received a $30 million upfront payment and is eligible for over $500 million in milestone payments.
TScan operates an internal good manufacturing practices facility for producing clinical supply of its TCR-T candidates and has engaged a global contract development and manufacturing organization to support potential commercialization. The company employs a non-viral gene delivery system based on transposons to enable cost-effective and consistent cell manufacturing. TScan's approach utilizes naturally occurring T cell receptors that can recognize both cell surface and intracellular cancer-specific antigens, offering advantages over competing CAR-T and TIL therapies. The company has established over twenty clinical trial sites for its lead program and continues advancing its pipeline through preclinical and clinical development stages.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 1783328
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns TScan Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · TScan Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do TScan Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of TScan Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in TScan Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”